

Product Data Sheet

Product Name: CCI-007
Cat. No.: GC61532

Chemical Properties

Cas. No. 939228-52-1

SMILES O=C(OCC)COC1=CC=C(/C=C(SC(N)=N2)\C2=O)C=C1OC


Formula $C_{15}H_{16}N_2O_5S$ M.Wt 336.36

Solubility DMSO: 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 80°C) Storage 4°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC₅₀ values of 2.5-6.2 μM in sensitive cells[1].

CCI-007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia[1]. Following CCI-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

007 treatment for 24h, significant mitochondrial depolarization was observed in PER-485 cells as evidenced by a shift in JC-1 signal[1]. Resistance to CCI-007 can occur by upregulation of MLL target gene expression[1]. CCI-007 reverts the aberrant elevated transcription of disease-driving factors HOXA9, MEIS1, and CMYC downstream of the pathogenic MLL fusion protein, thereby inducing MLL-r leukemia cell death[2]. Cell Viability Assay[1] Cell Line: PER-485, MOLM-13, MV4;11 cells.

[1]. Klaartje Somers, et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. *Oncotarget*. 2016 Jul 19;7(29):46067-46087. [2]. Klaartje Somers, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. *Oncogene*. 2019 May;38(20):3824-3842.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA